Axel Grothey
About
Axel Grothey is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Axel Grothey has authored 82 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 17 papers in Cancer Research. Recurrent topics in Axel Grothey's work include Colorectal Cancer Treatments and Studies (48 papers), Cancer Treatment and Pharmacology (32 papers) and Genetic factors in colorectal cancer (14 papers). Axel Grothey is often cited by papers focused on Colorectal Cancer Treatments and Studies (48 papers), Cancer Treatment and Pharmacology (32 papers) and Genetic factors in colorectal cancer (14 papers). Axel Grothey collaborates with scholars based in United States, Germany and France. Axel Grothey's co-authors include Hans‐Joachim Schmoll, Daniel J. Sargent, Richard M. Goldberg, Evanthia Galanis, Wolfram C. M. Dempke, Wolfgang E. Fleig, G. Kleber, Dorothea Wagner, Johannes Haerting and Susanne Unverzagt and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.
In The Last Decade
Axel Grothey
76 papers receiving 3.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Axel Grothey United States | 23 | 2.0k | 1.0k | 654 | 515 | 465 | 82 | 3.3k | ||
| René Bruno France | 35 | 2.8k 1.4× | 1.0k 1.0× | 913 1.4× | 248 0.5× | 184 0.4× | 128 | 4.7k | ||
| Tetsuya Hamaguchi Japan | 37 | 2.3k 1.1× | 1.2k 1.2× | 1.4k 2.1× | 804 1.6× | 276 0.6× | 217 | 4.5k | ||
| Yasutsuna Sasaki Japan | 35 | 2.6k 1.3× | 1.2k 1.2× | 1.2k 1.9× | 435 0.8× | 169 0.4× | 193 | 4.0k | ||
| Frans Erdkamp Netherlands | 26 | 2.7k 1.3× | 1.3k 1.3× | 572 0.9× | 377 0.7× | 465 1.0× | 82 | 3.7k | ||
| María José Lechuga United States | 14 | 754 0.4× | 672 0.7× | 510 0.8× | 316 0.6× | 731 1.6× | 25 | 2.3k | ||
| Albert Abad Spain | 28 | 2.5k 1.2× | 1.6k 1.6× | 1.2k 1.8× | 489 0.9× | 322 0.7× | 84 | 4.2k | ||
| Romain Coriat France | 40 | 2.7k 1.3× | 1.6k 1.6× | 760 1.2× | 1.3k 2.4× | 485 1.0× | 287 | 5.2k | ||
| Sharlene Gill Canada | 34 | 3.5k 1.7× | 1.1k 1.1× | 774 1.2× | 848 1.6× | 368 0.8× | 208 | 4.9k | ||
| Renuka Iyer United States | 31 | 1.5k 0.7× | 753 0.7× | 573 0.9× | 755 1.5× | 419 0.9× | 178 | 3.0k | ||
| M. E. Scheulen Germany | 36 | 2.6k 1.3× | 1.2k 1.2× | 2.3k 3.5× | 422 0.8× | 390 0.8× | 178 | 5.5k |
Countries citing papers authored by Axel Grothey
Since
Specialization
Citations
This map shows the geographic impact of Axel Grothey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel Grothey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel Grothey more than expected).
Fields of papers citing papers by Axel Grothey
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Axel Grothey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel Grothey. The network helps show where Axel Grothey may publish in the future.
Co-authorship network of co-authors of Axel Grothey
This figure shows the co-authorship network connecting the top 25 collaborators of Axel Grothey. A scholar is included among the top collaborators of Axel Grothey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Axel Grothey. Axel Grothey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sobrero, Alberto, Axel Grothey, Timothy Iveson, et al.. (2018). The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?. Annals of Oncology. 29(5). 1099–1107.
2.
Sara, Jaskanwal Deep Singh, Jasvinder Kaur, Ryan B. Khodadadi, et al.. (2018). 5-fluorouracil and cardiotoxicity: a review. Therapeutic Advances in Medical Oncology. 10.
3.
Major‐Elechi, Brittny, Paul J. Novotny, Jasvinder A. Singh, et al.. (2018). Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance). International Journal of Statistics in Medical Research. 7(4). 137–146.
4.
Grothey, Axel, Manish A. Shah, Takayuki Yoshino, et al.. (2017). CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 35(15_suppl). TPS3619–TPS3619.
5.
Hecht, J. Randolph, Jean‐Yves Douillard, Lee S. Schwartzberg, et al.. (2015). Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treatment Reviews. 41(8). 653–659.
6.
Renfro, Lindsay A., Axel Grothey, James Paul, et al.. (2014). Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting Analysis Dates for the IDEA Collaboration. SHILAP Revista de lepidopterología. 5(2). 1–7.
7.
Renfro, Lindsay A., Axel Grothey, Leonard B. Saltz, et al.. (2014). ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer. JNCI Journal of the National Cancer Institute. 106(12).
8.
Shi, Qian, Aimery de Gramont, Marc Buyse, et al.. (2013). Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database.. Journal of Clinical Oncology. 31(15_suppl). 3533–3533.
9.
Warsame, Rahma, et al.. (2012). Treatment options for advanced pancreatic cancer.
10.
Heinemann, Volker, Axel Grothey, Salvatore Siena, et al.. (2012). Randomisierte, doppelblinde, placebo-kontrollierte Phase III Multicenterstudie (CORRECT) von Regorafenib plus Best Supportive Care (BSC) versus Placebo plus BSC bei Patienten (Pat) mit metastasiertem kolorektalem Karzinom (mCRC), die nach einer Standardtherapie progredient waren. Zeitschrift für Gastroenterologie. 50(8).
11.
Shi, Qian, Greg Yothers, Thierry André, et al.. (2011). Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database.. Journal of Clinical Oncology. 29(15_suppl). 3556–3556.
12.
Erlichman, Charles, Martín E. Fernández-Zapico, Mitesh J. Borad, et al.. (2010). Abstract 1807: Phase I trial of the combined targeting of the Hedgehog (GDC-0449) and EGFR pathways (erlotinib) in pancreatic cancer. Cancer Research. 70(8_Supplement). 1807–1807.
13.
Wagner, Dorothea, Susanne Unverzagt, Wilfried Grothe, et al.. (2010). Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews. CD004064–CD004064.
14.
Jordan, Karin, Axel Grothey, Tanja Pelz, et al.. (2009). Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting. European Journal of Cancer Care. 19(5). 603–609.
15.
Grothey, Axel, et al.. (2008). Use of baseline quality of life (QOL) as compared with performance status (PS) as prognostic factors for overall survival (OS) in patients with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 26(15_suppl). 4016–4016.
16.
Hieke, K, Ulrich R. Kleeberg, Martina Stauch, & Axel Grothey. (2004). Costs of treatment of colorectal cancer in different settings in Germany. The European Journal of Health Economics. 5(3). 270–273.
17.
Cutsem, Eric Van, et al.. (2004). Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®). European Journal of Oncology Nursing. 8. S16–S30.
18.
Grothey, Axel, et al.. (1999). Biweekly docetaxel (DOC), gemcitabine (GEM), oxaliplatin (LOHP) in heavily pretreated patients with solid tumors — Preliminary results of a phase I study. European Journal of Cancer. 35. S288–S288.
19.
Grothey, Axel, et al.. (1999). Diagnostisches und therapeutisches Management der oberen Einflußstauung. Medizinische Klinik. 94(12). 681–684.
20.
Donhuijsen, K, et al.. (1991). [Zygomycoses: clinical aspects and pathology in 10 patients].. PubMed. 121(41). 1493–8.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by René Bruno Breakdown of academic impact, for papers by Tetsuya Hamaguchi Breakdown of academic impact, for papers by Yasutsuna Sasaki Breakdown of academic impact, for papers by Frans Erdkamp Breakdown of academic impact, for papers by María José Lechuga Breakdown of academic impact, for papers by Albert Abad Breakdown of academic impact, for papers by Romain Coriat Breakdown of academic impact, for papers by Sharlene Gill Breakdown of academic impact, for papers by Renuka Iyer Breakdown of academic impact, for papers by M. E. Scheulen